Clinical trials: Prostatic Neoplasm
Prostatectomy
A Comparison of Radical Prostatectomy and Precision Prostatectomy in Low- and Intermediate-risk Prostate Cancers.
Prostate cancer (PCa) management for low- and intermediate-risk patients often involves radical prostatectomy (RP), which achieves oncologic control but is associated with significant functional impairments, such as erectile…
- Trial name
- NCT07348367
- Testing
- Radical Prostatectomy, Precision Prostatectomy
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Henry Ford Health System
Prostate Cancer, Head and Neck Cancer
Ultrasound Spectroscopy as Early Indicators of Radiation Treatment Response in Prostate, Rectum and Head & Neck Cancers
Our objective in this study is to identify an optimal ultrasound spectroscopy parameter that can be used as an early predictor of pathological complete or partial response in men with prostate cancer and men and women with rectum…
- Conditions
- Prostate Cancer, Head and Neck Cancer, Rectal Cancer
- Trial name
- NCT03908684
- Testing
- Ultrasound Imaging
- Where
- Canada
- Volunteers
- 320 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer, PSA
Prostate Biopsy, Transrectal vs. Transperineal: Efficacy and Complications
This study evaluates the difference between 2 prostate biopsy methods, transrectal (through the rectal wall) and transperineal (through the skin) needle biopsy.
- Conditions
- Prostate Cancer, PSA, Infection
- Trial name
- ProBE-PC (NCT04081636)
- Testing
- Systematic Transrectal biopsy (TR-Bx), Targeted Transrectal biopsy (TR-Bx), Systematic Transperineal biopsy (TP-Bx)
- Where
- United States
- Volunteers
- 840 people
- Sponsor
- Albany Medical College
Castration-resistant Prostate Cancer
Long-Term Specified Drug Use-Results Survey for Xtandi Capsule
The purpose of this study is to confirm the long term safety and efficacy of enzalutamide in patients.
- Trial name
- NCT02669771
- Testing
- enzalutamide
- Where
- 47 sites in Japan
- Volunteers
- 1,018 people
- Sponsor
- Astellas Pharma Inc
Prostate Cancer Metastatic
Radiotherapy to Consolidate Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)
This will be a pragmatic, phase II, registry-based cohort-multiple randomized controlled trial (cmRCT) embedded within an ongoing prospective cancer radiotherapy registry.
- Trial name
- ANCHORProstate (NCT05457699)
- Testing
- Metastasis directed radiotherapy (MDRT), no MDRT
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Prostate Cancer
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate or Salivary Gland Cancer
This study will use PET scans, which is a type of x-ray test that uses a radiotracer, to see whether these scans may be better able to find places in the body where your prostate cancer may have spread.
- Trial name
- NCT00588185
- Testing
- [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
- Where
- 7 sites in United States
- Volunteers
- 300 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer, Endometrial Cancer
Adaptive Radiotherapy for Safe Hypofractionation
This phase II, registry-based cohort-multiple randomized controlled trial (cmRCT) evaluates whether daily online adaptive radiotherapy (ART) enables the safe delivery of hypofractionated, iso-biologically equivalent (EQD2)…
- Conditions
- Cancer, Endometrial Cancer, Prostate Cancer, Cervical Cancer
- Trial name
- ART-Hypo (NCT07516210)
- Testing
- Adaptive Hypofractionated Radiotherapy, Standard-of-care Radiotherapy
- Where
- Canada
- Volunteers
- 264 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Prostate Cancer
Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
The goal of this clinical research study is to find out if a therapy using docetaxel chemotherapy with hormonal therapy taken before your scheduled surgery is beneficial to treatment of prostate cancer.
- Trial name
- NCT01076335
- Testing
- Neoadjuvant Hormonal Therapy, Docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Urinary Stones, Prostate Cancer
Development of an AI-Agent for Urological Disease Diagnosis and Treatment
Urological diseases such as urinary stones, prostate cancer, and bladder cancer are very common and often require highly specialized diagnosis and treatment.
- Conditions
- Urinary Stones, Prostate Cancer, Bladder Cancer
- Trial name
- NCT07721935
- Where
- 3 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Prostate Cancer
APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
Phase II trial to study the effectiveness of APC8015 combined with bevacizumab in treating patients who have undergone radiation therapy and/or surgery and who have progressive prostate cancer.
- Trial name
- NCT00027599
- Testing
- bevacizumab, prostatic acid phosphatase-sargramostim fusion protein, sipuleucel-T
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Prostate Cancer
Improving the Quality of Radiotherapy by Multi-Institution Knowledge-Based Planning Optimization Models (Acronym: MIKAPOCo, Multi-Institutional Knowledge-based Approach in Plan Optimization for the Community)
Investigators central hypothesis is that it is possible to create libraries of "consistent" Knowledge-Based plan-models derived from large Institutional experiences.
- Trial name
- MIKAPOCo (NCT06317948)
- Testing
- treatment plan comparison
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Ospedale San Raffaele
Prostate Cancer
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells.
- Trial name
- NCT00002855
- Testing
- Bicalutamide, Doxorubicin hydrochloride, Estramustine Phosphate Sodium
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- M.D. Anderson Cancer Center
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial
This phase II trial evaluates an imaging technique (rhPSMA-7.3 positron emission tomography [PET]/computed tomography [CT]) for detecting prostate cancer in patients who have increasing prostate-specific antigen levels following…
- Trial name
- NCT06813898
- Testing
- Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Northwestern University
Diagnoses Disease
Micro-Ultrasound/Magnetic Resonance Imaging 001
Micro-ultrasound is a novel real-time imaging modality which maintains the clinical workflow of conventional ultrasound-guided prostate biopsy, while potentially maintaining a similar ability to detect clinically significant…
- Trial name
- NCT03938376
- Testing
- Micro-Ultrasound guided biopsy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Prostatic Neoplasms
Engaging Newly Diagnosed Men About Cancer Treatment Options
This research is being done to better understand how a new lab test called the Oncotype DX Prostate Cancer Assay may impact what treatment men decide to get and how they feel and think about their choice of treatment.
- Trial name
- ENACT (NCT02668276)
- Testing
- Standard NCCN counseling, Standard NCCN counseling and Oncotype DX results
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- University of Illinois Chicago
Prostate Cancer
An Observational Study of Radiotherapy After Injection of SpaceOAR Hydrogel
This observational study aims to evaluate the safety and effectiveness of radiotherapy for subjects with localized T1-T2 prostate cancer in China who were injected with SpaceOAR Hydrogel, via collecting clinical data related to…
- Trial name
- NCT05735652
- Testing
- SpaceOAR Hydrogel
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Boston Scientific Corporation
Prostate Cancer
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens.
- Trial name
- NCT00110162
- Testing
- antiandrogen therapy, releasing hormone agonist therapy, orchiectomy
- Where
- 20 sites in Australia, New Zealand
- Volunteers
- 2,000 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostate Cancer
Intra-operative Trans-rectal Ultrasound Guidance for Robot-assisted Radical Prostatectomy
Radical prostatectomy, or the surgical extirpation of the prostate, is a standard treatment for prostate cancer. The state of the art radical prostatectomy involves a robotic laparoscopic surgery system (the da Vinci) which…
- Trial name
- TRUS-RP (NCT02001597)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of British Columbia
Prostate Cancer
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for the treatment of men with prostate cancer who are starting long-term ADT for the first time, termed hormone-naïve prostate cancer.
- Trial name
- STAMPEDE (NCT00268476)
- Testing
- Celecoxib, Docetaxel, Prednisolone
- Where
- 120 sites in Switzerland, United Kingdom
- Volunteers
- 11,992 people
- Sponsor
- Medical Research Council